Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ACAD

Stock Name	ACADIA Pharmaceuticals Inc
Ticker	ACAD(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0042251084
LEI	529900O3044NO0PEA039

Show aggregate ACAD holdings

News associated with ACAD

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $28.88: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has […] - 2025-09-12 02:48:53
UBS Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price target increased by investment analysts at UBS Group from $36.00 to $39.00 in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential upside of 63.87% from the […] - 2025-09-11 02:49:04
Deutsche Bank AG Has $12.63 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Deutsche Bank AG trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 760,594 shares of the biopharmaceutical company’s stock after selling 281,853 shares during the period. Deutsche Bank AG owned […] - 2025-08-15 05:17:01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank: Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,256 shares of the biopharmaceutical company’s stock after purchasing an additional 3,389 shares during the period. […] - 2025-08-08 04:56:48
Mackenzie Financial Corp Grows Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Mackenzie Financial Corp boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,379 shares of the biopharmaceutical company’s stock after buying an additional 7,314 shares during the period. Mackenzie […] - 2025-08-06 04:36:58
Envestnet Asset Management Inc. Buys 36,003 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 33.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 142,667 shares of the biopharmaceutical company’s stock after acquiring an additional 36,003 shares during the period. Envestnet Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $2,370,000 […] - 2025-07-29 04:08:59
Analysts Predict 15% Upside For The Holdings of IJR: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 10:46:16
Cerity Partners LLC Sells 3,872 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 18.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,587 shares of the biopharmaceutical company’s stock after selling 3,872 shares during the period. Cerity Partners LLC’s holdings in ACADIA Pharmaceuticals were […] - 2025-07-28 04:46:48
Xponance Inc. Acquires 1,434 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Xponance Inc. boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,585 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the quarter. Xponance Inc.’s holdings in ACADIA Pharmaceuticals were worth $192,000 as of its […] - 2025-07-21 06:12:11
Bank of New York Mellon Corp Boosts Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of New York Mellon Corp boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 96.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,390 shares of the biopharmaceutical company’s stock after acquiring an additional 394,640 shares during […] - 2025-07-21 04:30:53
New York State Teachers Retirement System Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): New York State Teachers Retirement System grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 547.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,625 shares of the biopharmaceutical company’s stock after acquiring an additional 28,435 shares during […] - 2025-07-11 05:34:49
72,125 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Illinois Municipal Retirement Fund: Illinois Municipal Retirement Fund bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 72,125 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000. Other […] - 2025-07-02 05:28:55
SG Americas Securities LLC Sells 2,465,581 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): SG Americas Securities LLC decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 99.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,150 shares of the biopharmaceutical company’s stock after selling 2,465,581 shares during the quarter. SG Americas […] - 2025-06-27 04:18:48
State of Alaska Department of Revenue Invests $1.13 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): State of Alaska Department of Revenue purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 68,225 shares of the biopharmaceutical company’s stock, valued at approximately $1,133,000. Several other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Principal […] - 2025-06-26 04:43:03
Royal Bank Of Canada Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price raised by stock analysts at Royal Bank Of Canada from $26.00 to $38.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of […] - 2025-06-25 02:36:49
KMDA vs. ACAD: Which Stock Is the Better Value Option?: KMDA vs. ACAD: Which Stock Is the Better Value Option? - 2025-06-18 12:40:06
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells $314,633.88 in Stock: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) Director Laura Brege sold 14,446 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 […] - 2025-06-09 05:36:49
ProShare Advisors LLC Has $763,000 Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): ProShare Advisors LLC increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 28.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,580 shares of the biopharmaceutical company’s stock after purchasing an additional 9,164 shares during the period. ProShare Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $763,000 […] - 2025-05-25 06:03:26
Bank of America Corp DE Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of America Corp DE raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 41.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 680,853 shares of the biopharmaceutical company’s stock after acquiring an additional 199,504 shares during the quarter. Bank of America Corp DE’s holdings in ACADIA Pharmaceuticals were worth […] - 2025-05-23 05:19:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $24.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lifted by Morgan Stanley from $20.00 to $24.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on ACAD. Wall […] - 2025-05-23 02:52:57
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 at Deutsche Bank Aktiengesellschaft: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price objective upped by research analysts at Deutsche Bank Aktiengesellschaft from $20.00 to $35.00 in a research note issued on Wednesday, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […] - 2025-05-23 02:52:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 3.5% Following Analyst Upgrade: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was up 3.5% during mid-day trading on Wednesday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $22.75 and last traded at $22.44. Approximately 376,453 shares traded hands during mid-day trading, a decline of 84% […] - 2025-05-23 02:03:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at StockNews.com: StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […] - 2025-05-22 04:50:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $32.00 Price Target at HC Wainwright: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price increased by equities researchers at HC Wainwright from $27.00 to $32.00 in a research report issued on Monday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 47.53% […] - 2025-05-21 02:42:45
Robert W. Baird Raises ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $31.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […] - 2025-05-20 02:36:58
Northern Trust Corp Has $22.61 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Northern Trust Corp increased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,232,366 shares of the biopharmaceutical company’s stock after buying an additional 106,236 shares during the period. Northern Trust Corp owned 0.74% […] - 2025-05-13 06:14:59
Traders Purchase Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw unusually large options trading activity on Thursday. Stock traders purchased 2,626 call options on the company. This is an increase of 146% compared to the average daily volume of 1,068 call options. Insider Buying and Selling In other news, Director Elizabeth A. Garofalo sold 4,919 shares […] - 2025-05-09 02:38:58
Envestnet Asset Management Inc. Decreases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. lessened its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,664 shares of the biopharmaceutical company’s stock after selling 12,037 shares during the quarter. Envestnet Asset […] - 2025-04-28 04:38:49
Legal & General Group Plc Sells 2,348 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Legal & General Group Plc cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,042 shares of the biopharmaceutical company’s stock after selling 2,348 shares during the quarter. Legal & General […] - 2025-04-25 05:16:54
Cerity Partners LLC Acquires 6,173 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,459 shares of the biopharmaceutical company’s stock after acquiring an additional 6,173 shares during the quarter. […] - 2025-04-24 04:52:50

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ACAD holdings

Date	Number of ACAD Shares Held	Base Market Value of ACAD Shares	Local Market Value of ACAD Shares	Change in ACAD Shares Held	Change in ACAD Base Value	Current Price per ACAD Share Held	Previous Price per ACAD Share Held
2025-11-11 (Tuesday)	109,979	USD 2,608,702	USD 2,608,702	0	USD 167,168	USD 23.72	USD 22.2
2025-11-10 (Monday)	109,979	USD 2,441,534	USD 2,441,534	281	USD -34,350	USD 22.2	USD 22.57
2025-11-07 (Friday)	109,698	USD 2,475,884	USD 2,475,884	0	USD 100,922	USD 22.57	USD 21.65
2025-11-06 (Thursday)	109,698	USD 2,374,962	USD 2,374,962	281	USD -68,320	USD 21.65	USD 22.33
2025-11-05 (Wednesday)	109,417	USD 2,443,282	USD 2,443,282	0	USD 52,521	USD 22.33	USD 21.85
2025-11-04 (Tuesday)	109,417	USD 2,390,761	USD 2,390,761	283	USD -50,567	USD 21.85	USD 22.37
2025-11-03 (Monday)	109,134	USD 2,441,328	USD 2,441,328	0	USD -36,014	USD 22.37	USD 22.7
2025-10-31 (Friday)	109,134	USD 2,477,342	USD 2,477,342	0	USD -4,365	USD 22.7	USD 22.74
2025-10-30 (Thursday)	109,134	USD 2,481,707	USD 2,481,707	1,415	USD 54,798	USD 22.74	USD 22.53
2025-10-29 (Wednesday)	107,719	USD 2,426,909	USD 2,426,909	566	USD 3,108	USD 22.53	USD 22.62
2025-10-28 (Tuesday)	107,153	USD 2,423,801	USD 2,423,801	0	USD -39,646	USD 22.62	USD 22.99
2025-10-27 (Monday)	107,153	USD 2,463,447	USD 2,463,447	0	USD 103,938	USD 22.99	USD 22.02

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ACAD by Blackrock for IE00BDZVHG35

Show aggregate share trades of ACAD

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 281 22.895 22.080 22.161 USD 6,227 18.90
2025-11-06 BUY 281 23.580 20.640 20.934 USD 5,882 18.86
2025-11-04 BUY 283 22.200 21.720 21.768 USD 6,160 18.83
2025-10-30 BUY 1,415 22.880 22.150 22.223 USD 31,446 18.76
2025-10-29 BUY 566 22.530 22.920 22.881 USD 12,951 18.74
2025-10-22 SELL -1,128 21.390 21.410 21.408 USD -24,148 18.65 Loss of -3,115 on sale
2025-10-20 BUY 564 20.940 21.340 21.300 USD 12,013 18.62
2025-10-17 BUY 1,409 20.890 21.070 21.052 USD 29,662 18.60
2025-10-15 BUY 2,248 21.740 21.920 21.902 USD 49,236 18.59
2025-10-03 BUY 1,946 21.800 21.850 21.845 USD 42,510 18.56
2025-10-02 BUY 278 21.380 21.490 21.479 USD 5,971 18.54
2025-09-30 BUY 556 21.340 21.480 21.466 USD 11,935 18.51
2025-09-26 BUY 556 21.050 21.400 21.365 USD 11,879 18.48
2025-09-25 BUY 556 21.210 21.360 21.345 USD 11,868 18.46
2025-09-18 BUY 290 24.760 24.800 24.796 USD 7,191 18.42
2025-09-17 BUY 873 24.200 24.930 24.857 USD 21,700 18.38
2025-09-11 SELL -291 24.200 24.460 24.434 USD -7,110 18.31 Loss of -1,781 on sale
2025-09-10 BUY 582 23.800 24.970 24.853 USD 14,464 18.28
2025-07-17 SELL -580 22.550 23.120 23.063 USD -13,377 18.16 Loss of -2,847 on sale
2025-07-16 BUY 1,266 22.550 22.620 22.613 USD 28,628 18.13
2025-07-11 SELL -2,296 20.980 22.140 22.024 USD -50,567 18.06 Loss of -9,108 on sale
2025-07-02 BUY 15,785 21.240 21.690 21.645 USD 341,666 17.96
2025-06-25 BUY 574 22.500 23.040 22.986 USD 13,194 17.85
2025-06-20 BUY 2,616 22.710 23.240 23.187 USD 60,657 17.75
2025-06-11 BUY 556 22.300 22.560 22.534 USD 12,529 17.51
2025-06-10 BUY 556 22.200 22.690 22.641 USD 12,588 17.47
2025-06-04 SELL -278 21.770 23.400 23.237 USD -6,460 17.33 Loss of -1,641 on sale
2025-04-23 BUY 278 14.620 14.980 14.944 USD 4,154 17.02
2025-04-10 SELL -2,224 14.110 14.760 14.695 USD -32,682 17.27 Profit of 5,721 on sale
2025-04-08 SELL -278 14.100 15.220 15.108 USD -4,200 17.33 Profit of 618 on sale
2025-04-07 SELL -278 14.610 15.700 15.591 USD -4,334 17.36 Profit of 492 on sale
2025-04-04 SELL -1,390 15.380 15.970 15.911 USD -22,116 17.39 Profit of 2,049 on sale
2025-04-01 BUY 2,516 16.320 16.770 16.725 USD 42,080 17.41
2025-03-31 SELL -822 16.610 16.880 16.853 USD -13,853 17.42 Profit of 464 on sale
2025-03-21 BUY 3,772 16.790 17.310 17.258 USD 65,097 17.44
2025-03-14 SELL -4,192 17.500 17.700 17.680 USD -74,115 17.46 Loss of -942 on sale
2025-03-07 SELL -524 17.560 17.860 17.830 USD -9,343 17.48 Loss of -182 on sale
2025-03-04 SELL -262 18.260 18.540 18.512 USD -4,850 17.46 Loss of -276 on sale
2025-02-25 BUY 524 19.010 19.720 19.649 USD 10,296 17.32
2025-02-19 SELL -261 19.670 20.060 20.021 USD -5,225 17.14 Loss of -753 on sale
2025-02-13 BUY 783 19.770 19.830 19.824 USD 15,522 16.92
2025-02-12 BUY 261 19.100 19.110 19.109 USD 4,987 16.87
2025-02-11 BUY 1,044 18.490 18.700 18.679 USD 19,501 16.84
2024-12-30 SELL -8,580 16.690 16.810 16.798 USD -144,127 16.04 Loss of -6,506 on sale
2024-11-18 SELL -4,260 17.030 17.170 17.156 USD -73,085 15.27 Loss of -8,056 on sale
2024-11-08 SELL -284 17.660 17.970 17.939 USD -5,095 14.90 Loss of -862 on sale
2024-10-21 SELL -285 14.760 15.560 15.480 USD -4,412 0.00 Loss of -4,412 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	281	22.895	22.080	22.161	USD 6,227	18.90
2025-11-06	BUY	281	23.580	20.640	20.934	USD 5,882	18.86
2025-11-04	BUY	283	22.200	21.720	21.768	USD 6,160	18.83
2025-10-30	BUY	1,415	22.880	22.150	22.223	USD 31,446	18.76
2025-10-29	BUY	566	22.530	22.920	22.881	USD 12,951	18.74
2025-10-22	SELL	-1,128	21.390	21.410	21.408	USD -24,148	18.65 Loss of -3,115 on sale
2025-10-20	BUY	564	20.940	21.340	21.300	USD 12,013	18.62
2025-10-17	BUY	1,409	20.890	21.070	21.052	USD 29,662	18.60
2025-10-15	BUY	2,248	21.740	21.920	21.902	USD 49,236	18.59
2025-10-03	BUY	1,946	21.800	21.850	21.845	USD 42,510	18.56
2025-10-02	BUY	278	21.380	21.490	21.479	USD 5,971	18.54
2025-09-30	BUY	556	21.340	21.480	21.466	USD 11,935	18.51
2025-09-26	BUY	556	21.050	21.400	21.365	USD 11,879	18.48
2025-09-25	BUY	556	21.210	21.360	21.345	USD 11,868	18.46
2025-09-18	BUY	290	24.760	24.800	24.796	USD 7,191	18.42
2025-09-17	BUY	873	24.200	24.930	24.857	USD 21,700	18.38
2025-09-11	SELL	-291	24.200	24.460	24.434	USD -7,110	18.31 Loss of -1,781 on sale
2025-09-10	BUY	582	23.800	24.970	24.853	USD 14,464	18.28
2025-07-17	SELL	-580	22.550	23.120	23.063	USD -13,377	18.16 Loss of -2,847 on sale
2025-07-16	BUY	1,266	22.550	22.620	22.613	USD 28,628	18.13
2025-07-11	SELL	-2,296	20.980	22.140	22.024	USD -50,567	18.06 Loss of -9,108 on sale
2025-07-02	BUY	15,785	21.240	21.690	21.645	USD 341,666	17.96
2025-06-25	BUY	574	22.500	23.040	22.986	USD 13,194	17.85
2025-06-20	BUY	2,616	22.710	23.240	23.187	USD 60,657	17.75
2025-06-11	BUY	556	22.300	22.560	22.534	USD 12,529	17.51
2025-06-10	BUY	556	22.200	22.690	22.641	USD 12,588	17.47
2025-06-04	SELL	-278	21.770	23.400	23.237	USD -6,460	17.33 Loss of -1,641 on sale
2025-04-23	BUY	278	14.620	14.980	14.944	USD 4,154	17.02
2025-04-10	SELL	-2,224	14.110	14.760	14.695	USD -32,682	17.27 Profit of 5,721 on sale
2025-04-08	SELL	-278	14.100	15.220	15.108	USD -4,200	17.33 Profit of 618 on sale
2025-04-07	SELL	-278	14.610	15.700	15.591	USD -4,334	17.36 Profit of 492 on sale
2025-04-04	SELL	-1,390	15.380	15.970	15.911	USD -22,116	17.39 Profit of 2,049 on sale
2025-04-01	BUY	2,516	16.320	16.770	16.725	USD 42,080	17.41
2025-03-31	SELL	-822	16.610	16.880	16.853	USD -13,853	17.42 Profit of 464 on sale
2025-03-21	BUY	3,772	16.790	17.310	17.258	USD 65,097	17.44
2025-03-14	SELL	-4,192	17.500	17.700	17.680	USD -74,115	17.46 Loss of -942 on sale
2025-03-07	SELL	-524	17.560	17.860	17.830	USD -9,343	17.48 Loss of -182 on sale
2025-03-04	SELL	-262	18.260	18.540	18.512	USD -4,850	17.46 Loss of -276 on sale
2025-02-25	BUY	524	19.010	19.720	19.649	USD 10,296	17.32
2025-02-19	SELL	-261	19.670	20.060	20.021	USD -5,225	17.14 Loss of -753 on sale
2025-02-13	BUY	783	19.770	19.830	19.824	USD 15,522	16.92
2025-02-12	BUY	261	19.100	19.110	19.109	USD 4,987	16.87
2025-02-11	BUY	1,044	18.490	18.700	18.679	USD 19,501	16.84
2024-12-30	SELL	-8,580	16.690	16.810	16.798	USD -144,127	16.04 Loss of -6,506 on sale
2024-11-18	SELL	-4,260	17.030	17.170	17.156	USD -73,085	15.27 Loss of -8,056 on sale
2024-11-08	SELL	-284	17.660	17.970	17.939	USD -5,095	14.90 Loss of -862 on sale
2024-10-21	SELL	-285	14.760	15.560	15.480	USD -4,412	0.00 Loss of -4,412 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ACAD

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	177,131	200	310,627	57.0%
2025-09-18	231,742	428	554,082	41.8%
2025-09-17	277,075	374	461,418	60.0%
2025-09-16	292,134	2,622	560,920	52.1%
2025-09-15	608,488	6,416	1,142,651	53.3%
2025-09-12	234,478	0	584,492	40.1%
2025-09-11	237,345	0	578,233	41.0%
2025-09-10	406,173	918	959,743	42.3%
2025-09-09	416,192	8,875	1,219,148	34.1%
2025-09-08	275,369	917	543,613	50.7%
2025-09-05	203,992	4,543	403,138	50.6%
2025-09-04	357,546	11,463	821,948	43.5%
2025-09-03	165,767	0	471,567	35.2%
2025-09-02	379,278	123,302	944,994	40.1%
2025-08-29	178,641	647	380,604	46.9%
2025-08-28	347,632	42,128	704,639	49.3%
2025-08-27	735,312	73,271	1,108,402	66.3%
2025-08-26	383,113	1,531	782,128	49.0%
2025-08-25	415,483	632	763,460	54.4%
2025-08-22	927,948	813	1,757,013	52.8%
2025-08-21	224,011	0	400,364	56.0%
2025-08-20	121,997	202	279,171	43.7%
2025-08-19	231,080	0	456,081	50.7%
2025-08-18	679,222	196	963,982	70.5%
2025-08-15	641,994	5,137	984,489	65.2%
2025-08-14	332,247	0	569,267	58.4%
2025-08-13	267,703	1,852	555,599	48.2%
2025-08-12	505,509	6,990	849,125	59.5%
2025-08-11	257,130	2,117	493,093	52.1%
2025-08-08	313,380	73	531,753	58.9%
2025-08-07	381,332	3,323	621,473	61.4%
2025-08-06	256,267	142	516,141	49.7%
2025-08-05	314,036	470	596,278	52.7%
2025-08-04	265,143	235	549,947	48.2%
2025-08-01	242,661	100	835,083	29.1%
2025-07-31	356,257	876	685,250	52.0%
2025-07-30	515,390	335	843,656	61.1%
2025-07-29	280,257	6,520	405,607	69.1%
2025-07-28	328,072	654	464,165	70.7%
2025-07-25	169,818	0	295,055	57.6%
2025-07-24	304,773	1,105	461,020	66.1%
2025-07-23	228,907	1,204	403,501	56.7%
2025-07-22	159,551	1,542	259,145	61.6%
2025-07-21	214,521	1	304,308	70.5%
2025-07-18	165,636	2,788	227,873	72.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE